BioVie announces positive Phase 2 results for NE3107 in Parkinson's and Alzheimer's; epigenetic age reduced 3.3 years

BIOVIE INC.

PD trial: NE3107+levodopa improved UPDRS Part 3 by 3+ points vs levodopa alone; under-70 patients saw 6-point superiority.
AD trial: 2.1-point improvement on ADAS-Cog12 (p=0.0173) in MCI/mild AD patients; CSF p-tau reduced by 1.66 pg/mL.
18 of 22 AD patients showed improvement on functional MRI; no drug-related adverse events reported.
DNA methylation analysis: Horvath SkinBlood clock reduced by 3.3 years (p=0.0021) after 3 months; 19 of 22 patients showed reduction.
Full Parkinson's data to be presented at AD/PD 2023 conference in March-April 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.